2015
A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress
Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLOS ONE 2015, 10: e0122628. PMID: 25897662, PMCID: PMC4405579, DOI: 10.1371/journal.pone.0122628.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAnilidesAntineoplastic AgentsApoptosis Regulatory ProteinsAutophagyAutophagy-Related Protein 7Bcl-2-Like Protein 11Cell Cycle CheckpointsCell Line, TumorCyclic AMP Response Element-Binding ProteinDrug Screening Assays, AntitumorEndoplasmic Reticulum StressHumansInhibitory Concentration 50Kaplan-Meier EstimateLung NeoplasmsMembrane ProteinsMolecular Docking SimulationOrganophosphatesPeptide FragmentsProportional Hazards ModelsProtein BindingProto-Oncogene ProteinsSialoglycoproteinsUbiquitin-Activating EnzymesConceptsLung cancerHuman lung cancer cell linesEndoplasmic reticulum (ER) stress markersLung cancer cell linesNovel therapeutic strategiesPotential therapeutic targetAnti-cancer effectsNovel small molecule inhibitorPotential therapeutic agentCyclic AMP response element binding proteinAccumulation of p62Response element-binding proteinEndoplasmic reticulum stressCancer cell linesCancer deathCommon subtypeCell cycle arrestLung adenocarcinomaNew therapiesTherapeutic strategiesSmall molecule inhibitorsTherapeutic targetElement-binding proteinStress markersTherapeutic agents
2010
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo. PLOS ONE 2010, 5: e14124. PMID: 21124782, PMCID: PMC2993951, DOI: 10.1371/journal.pone.0014124.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzimidazolesCarcinoma, Non-Small-Cell LungCell CycleCell Line, TumorCell SurvivalDose-Response Relationship, DrugDrug SynergismFemaleHeterocyclic Compounds, 3-RingHumansLung NeoplasmsMiceMice, Inbred BALB CMice, NudeMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins c-aktSignal TransductionSurvival AnalysisTumor BurdenXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerCell lung cancerCombination of AZD6244Lung cancer cell linesCombination therapyLung cancerCancer cell linesTumor growthTumor tissueHuman non-small cell lung cancerLung cancer cell growthCell linesHuman lung cancer cell linesSingle drug treatmentSynergistic antitumor activityHuman lung tumorsAnimal survival timeMean animal survival timeCancer cell growthXenograft tumor growthP-AKT expressionLung tumorsDrug treatmentDrug combinationsSurvival time
2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activityTargeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Molecular Cancer Therapeutics 2002, 1: 595-600. PMID: 12479219.Peer-Reviewed Original ResearchMeSH KeywordsADP Ribose TransferasesAnimalsBacterial ToxinsDose-Response Relationship, DrugExotoxinsFlow CytometryHumansImmunoglobulin FragmentsImmunotherapyKineticsLung NeoplasmsMesothelinMiceMice, NudeMicroscopy, FluorescenceMutationNeoplasm TransplantationPseudomonasRecombinant ProteinsTumor Cells, CulturedVirulence FactorsConceptsTargeted therapyNude miceHuman non-small cell lung cancer cellsNon-small cell lung cancer cellsNCI-H226 cellsHuman lung cancer cell linesCell lung cancer cellsSquamous cell carcinomaLung cancer cell linesHuman lung cancerExperimental lung metastasisLung cancer cellsPC14PE6 cellsCancer cell linesLung metastasesCell carcinomaCancer patientsLung cancerOvarian cancerNontoxic doseMesothelinDay 7Recombinant immunotoxinCertain cancersCancerIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
Herbst R, Hong W. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. DOI: 10.1016/s0093-7754(02)70087-0.Peer-Reviewed Original ResearchSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activity
2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
Herbst R, Kim E, Harari P. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-732. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Anti-epidermal growth factor receptor monoclonal antibodyAnti-EGFR monoclonal antibodiesMonoclonal antibodiesLocoregional disease recurrenceImportant adverse eventsPhase I studiesReceptor monoclonal antibodyExcellent response ratesTreatment of headHuman tumor xenograftsExtracellular receptor sitesInhibition of metastasisEnhanced tumor invasionPotent antitumour activityAnticancer treatment strategiesGrowth factor receptorCancer cell linesAdverse eventsRefractory diseaseSkin rashWeekly infusionsDisease recurrence
2000
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.
Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research 2000, 60: 4959-67. PMID: 10987313.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain NeoplasmsCell DivisionCytokinesDNA, AntisenseEndothelial Growth FactorsHumansLymphokinesMaleMiceMice, NudeNeoplasm TransplantationNeovascularization, PathologicRNA, MessengerTransfectionTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsBrain metastasesCell carcinomaHuman lung squamous carcinoma cellsLung squamous carcinoma cellsLung squamous cell carcinomaExperimental brain metastasesParenchymal brain metastasesSquamous cell carcinomaInternal carotid arteryVascular endothelial growth factorRenal cell carcinomaEndothelial growth factorImportant therapeutic targetInhibition of VEGFSquamous carcinoma cellsLung adenocarcinoma cellsCancer cell linesDifferent human cancer cell linesCarotid arteryNude miceTherapeutic targetKM12SM cellsMetastasisHuman cancer cell linesVEGF expression